GMAB Genmab - ADR

20.03
+0.14  (+1%)
Previous Close 19.89
Open 19.94
Price To Book 10.71
Market Cap 12,977,455,628
Shares 647,900,930
Volume 239,428
Short Ratio
Av. Daily Volume 472,451

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2020.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
Phase 3 data due 3Q 2019.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
BLA filing announced July 10, 2019.
Teprotumumab
Thyroid Eye Disease (TED)
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer
FDA Approval announced June 28, 2019.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
sBLA filing announced July 12, 2019. PDUFA estimate May 12, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
PDUFA date September 26, 2019.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Phase 1/2 initial data due 2019.
Enapotamab vedotin
Solid tumors
Phase 1/2 initial data due 2019.
HexaBody-DR5/DR5
Solid tumors
Phase 1/2 initial data due 2019.
DuoBody-CD3xCD20
B-cell Lymphoma